vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and John Marshall Bancorp, Inc. (JMSB). Click either name above to swap in a different company.
John Marshall Bancorp, Inc. is the larger business by last-quarter revenue ($16.8M vs $9.5M, roughly 1.8× Cellectis S.A.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -265.9%, a 302.2% gap on every dollar of revenue.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
CLLS vs JMSB — Head-to-Head
Income Statement — Q2 FY2024 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $16.8M |
| Net Profit | $-25.3M | $6.1M |
| Gross Margin | — | — |
| Operating Margin | -181.1% | — |
| Net Margin | -265.9% | 36.3% |
| Revenue YoY | 375.0% | — |
| Net Profit YoY | -51.9% | 26.8% |
| EPS (diluted) | $-0.28 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $16.8M | ||
| Q4 25 | — | $16.4M | ||
| Q3 25 | — | $16.3M | ||
| Q2 25 | — | $15.4M | ||
| Q1 25 | — | $14.6M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | — | $13.8M | ||
| Q2 24 | $9.5M | $12.6M |
| Q1 26 | — | $6.1M | ||
| Q4 25 | — | $5.9M | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | — | $5.1M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | $-25.3M | $3.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 47.4% | ||
| Q3 25 | — | 42.2% | ||
| Q2 25 | — | 42.7% | ||
| Q1 25 | — | 42.4% | ||
| Q4 24 | — | 42.5% | ||
| Q3 24 | — | 38.8% | ||
| Q2 24 | -181.1% | 39.7% |
| Q1 26 | — | 36.3% | ||
| Q4 25 | — | 36.2% | ||
| Q3 25 | — | 33.2% | ||
| Q2 25 | — | 33.1% | ||
| Q1 25 | — | 32.9% | ||
| Q4 24 | — | 33.3% | ||
| Q3 24 | — | 30.7% | ||
| Q2 24 | -265.9% | 30.9% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | — | $0.41 | ||
| Q3 25 | — | $0.38 | ||
| Q2 25 | — | $0.36 | ||
| Q1 25 | — | $0.34 | ||
| Q4 24 | — | $0.33 | ||
| Q3 24 | — | $0.30 | ||
| Q2 24 | $-0.28 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $150.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $268.1M |
| Total Assets | $407.1M | $2.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $150.2M | ||
| Q4 25 | — | $130.0M | ||
| Q3 25 | — | $163.6M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $169.1M | ||
| Q4 24 | — | $122.5M | ||
| Q3 24 | — | $177.2M | ||
| Q2 24 | $149.0M | $182.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $80.9M | ||
| Q3 25 | — | $80.9M | ||
| Q2 25 | — | $80.8M | ||
| Q1 25 | — | $80.8M | ||
| Q4 24 | — | $80.8M | ||
| Q3 24 | — | $80.8M | ||
| Q2 24 | — | $24.7M |
| Q1 26 | — | $268.1M | ||
| Q4 25 | — | $265.6M | ||
| Q3 25 | — | $259.7M | ||
| Q2 25 | — | $253.7M | ||
| Q1 25 | — | $253.0M | ||
| Q4 24 | — | $246.6M | ||
| Q3 24 | — | $243.1M | ||
| Q2 24 | $148.6M | $235.3M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $407.1M | $2.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.33× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | — |
| Free Cash FlowOCF − Capex | $27.6M | — |
| FCF MarginFCF / Revenue | 290.5% | — |
| Capex IntensityCapex / Revenue | 13.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $22.6M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $7.5M | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $1.4M | ||
| Q2 24 | $28.9M | $10.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.0M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $7.4M | ||
| Q1 25 | — | $6.6M | ||
| Q4 24 | — | $16.8M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | $27.6M | $10.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 134.7% | ||
| Q3 25 | — | 7.3% | ||
| Q2 25 | — | 47.8% | ||
| Q1 25 | — | 45.3% | ||
| Q4 24 | — | 116.9% | ||
| Q3 24 | — | 9.5% | ||
| Q2 24 | 290.5% | 80.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | 13.2% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | — | 3.61× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 2.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLLS
Segment breakdown not available.
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
